Literature DB >> 8162467

Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases.

C P Denton1, P Sweny, A Abdulla, C M Black.   

Abstract

Cyclosporin A, which is a nephrotoxic agent, has been a mainstay antirejection drug in heart, kidney and lung transplant programmes for about 10 yr. Renal transplant physicians have become adept in balancing its powerful immunosuppressive effects with its undoubted potential nephrotoxicity. Here we report three of eight systemic sclerosis (SSc) patients treated with cyclosporin A who developed acute renal failure. Consideration is given to the evidence of benefit from this agent in SSc and to the management of acute hypertensive renal failure in this disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162467     DOI: 10.1093/rheumatology/33.1.90

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  14 in total

Review 1.  Combination therapies for systemic sclerosis.

Authors:  C P Denton; C M Black
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Scleroderma renal crisis: new insights and developments.

Authors:  Elisa Y Rhew; Walter G Barr
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

Review 3.  Immunomodulatory therapy for SSc: will high-intensity immunosuppression with stem cell rescue improve outcome?

Authors:  Leslie J Crofford
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 4.  Immunotherapy of systemic sclerosis.

Authors:  Rebecca Manno; Francesco Boin
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

Review 5.  Drug treatment of scleroderma.

Authors:  C Leighton
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Scleroderma renal crisis: a review for emergency physicians.

Authors:  Tim Montrief; Alex Koyfman; Brit Long
Journal:  Intern Emerg Med       Date:  2019-05-10       Impact factor: 3.397

Review 7.  The scleroderma kidney: progress in risk factors, therapy, and prevention.

Authors:  Guillaume Bussone; Alice Bérezné; Vincent Pestre; Loïc Guillevin; Luc Mouthon
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 8.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

Review 9.  [Renal manifestations of rheumatic diseases].

Authors:  A Schwarting; E Märker-Hermann
Journal:  Z Rheumatol       Date:  2005-02       Impact factor: 1.372

Review 10.  Scleroderma renal crisis: a rare but severe complication of systemic sclerosis.

Authors:  Luc Mouthon; Alice Bérezné; Guillaume Bussone; Laure-Hélène Noël; Peter M Villiger; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.